Aura Biosciences Inc (AURA NASDAQ) stock market data APIs
$7.3474
0.19(2.6%)
as of September 3, 2026
Try our APIs with
free plan!
Aura Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Prev. Close
7.3474
Open
7.5396
High
7.5784
Low
7.3289
52 wk Range
4.73-9.535
Market Cap
778 M
Shares Outstanding
104 M
EPS
-0.48
Beta
0.396
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aura Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aura Biosciences Inc data using free add-ons & libraries
Get Aura Biosciences Inc Fundamental Data
Aura Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -136 992 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-11
- EPS/Forecast: -0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aura Biosciences Inc News
New
Aura Biosciences GAAP EPS of -$0.48 misses by $0.10
* Aura Biosciences press release [https://seekingalpha.com/pr/20614282-aura-biosciences-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (AURA [https://seekingalpha.com/...
Friday Sector Leaders: Precious Metals, Advertising Stocks
In trading on Friday, precious metals shares were relative leaders, up on the day by about 6.7%. Leading the group were shares of B2Gold, up about 14.6% and shares of Aura Minerals up about 12.6% on ...
Top Biotech Gainers: PPCB Launches Share Buyback, VRXA Partners With ATUM, SLS On Watch
(RTTNews) - Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch o...
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumo...
Get Aura Biosciences Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
